- Home
- SRZN vs PBYI Comparison
SRZN vs PBYI Comparison
Compare SRZN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | PBYI |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.0M | 343.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | SRZN | PBYI |
|---|---|---|
| Price | $25.84 | $6.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 85.8K | ★ 254.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $75.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $3.03 |
| 52 Week High | $35.00 | $7.90 |
Technical Indicators
Market Signals| Indicator | SRZN | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 38.80 |
| Support Level | $23.95 | $6.32 |
| Resistance Level | $29.18 | $7.25 |
| Average True Range (ATR) | 2.39 | 0.36 |
| MACD | -0.74 | -0.10 |
| Stochastic Oscillator | 2.34 | 14.17 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.